Microtech has initiated human clinical trials for its advanced implantable microsensor platform for better management of heart failure. The first implantation was performed by Prof. Erez Sharoni of Cardio-Thoracic Surgery Beilinson Medical Center in Israel.
It holds a small size (sub-millimeter), doesn’t require a power supply, and shares information through ultrasound signals. It can work independently or be embedded into currently existing implants. Moreover, it is also turning them into smart devices capable of real-time data acquisition as well as multitasking.
Microtech: Benefits for Heart Failure Patients
In an interview with Prof. Sharoni, he stated, “This amazing technology could revolutionize the care of patients with heart failure, more so those who are implanted with LVADs or have undergone heart transplant.”
Dr. Tuvia Ben-Gal, Head of Heart Failure at Rabin Medical Center, stressed its relevance, speaking for patient benefits. Heart failure is characterized by periods of improvement and decline and may need admission to the hospital. This also helps in constant or real-time monitoring, which means earlier intervention, thus leading to decreased morbidity and mortality.
Issues Relating to Increased Subscriber Conversions
It is noteworthy that this has the potential to revolutionize not only heart failure. Dr. Yoram Richter, CEO of Medinol, further noted its flexibility, saying, “Thanks to the microtech implants, data can be transferred to physicians with precision regardless of if a patient is immobile or travels a lot.
This invention is the savior for diseases like glaucoma, hydrocephalus, and portal hypertension, which help in less hospitalization and fair treatment for everyone.
The trial is a landmark in the medical technology field as it presents a possibility of enhanced patient care and management of health systems globally.
